Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Fate Therapeutics (FATE) over the last 14 years, with Q3 2025 value amounting to $40.6 million.

  • Fate Therapeutics' Cash & Equivalents rose 715.66% to $40.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.6 million, marking a year-over-year increase of 715.66%. This contributed to the annual value of $36.1 million for FY2024, which is 1388.58% down from last year.
  • Latest data reveals that Fate Therapeutics reported Cash & Equivalents of $40.6 million as of Q3 2025, which was up 715.66% from $41.2 million recorded in Q2 2025.
  • Over the past 5 years, Fate Therapeutics' Cash & Equivalents peaked at $133.6 million during Q4 2021, and registered a low of $33.3 million during Q3 2023.
  • Over the past 5 years, Fate Therapeutics' median Cash & Equivalents value was $46.8 million (recorded in 2023), while the average stood at $64.9 million.
  • Per our database at Business Quant, Fate Therapeutics' Cash & Equivalents tumbled by 8230.0% in 2021 and then surged by 18872.44% in 2024.
  • Quarter analysis of 5 years shows Fate Therapeutics' Cash & Equivalents stood at $133.6 million in 2021, then plummeted by 54.09% to $61.3 million in 2022, then plummeted by 31.73% to $41.9 million in 2023, then decreased by 13.89% to $36.1 million in 2024, then increased by 12.66% to $40.6 million in 2025.
  • Its Cash & Equivalents stands at $40.6 million for Q3 2025, versus $41.2 million for Q2 2025 and $44.9 million for Q1 2025.